{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:31:57Z","timestamp":1777926717646,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771753"],"award-info":[{"award-number":["81771753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.intimp.2019.03.055","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T05:07:38Z","timestamp":1554181658000},"page":"350-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["CD30 ligand deficiency accelerates glioma progression by promoting the formation of tumor immune microenvironment"],"prefix":"10.1016","volume":"71","author":[{"given":"Jin","family":"Duan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunobu","family":"Yoshikai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.03.055_bb0005","doi-asserted-by":"crossref","unstructured":". Desjardins, A., et al., Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med., 2018. 379(2): p. 150\u2013161.","DOI":"10.1056\/NEJMoa1716435"},{"key":"10.1016\/j.intimp.2019.03.055_bb0010","doi-asserted-by":"crossref","unstructured":"Gieryng, A., et al., Immune microenvironment of gliomas. Lab. Investig., 2017. 97(5): p. 498\u2013518.","DOI":"10.1038\/labinvest.2017.19"},{"issue":"3","key":"10.1016\/j.intimp.2019.03.055_bb0015","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2019.03.055_bb0020","doi-asserted-by":"crossref","unstructured":"Mizutani, M., et al., The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J. Immunol., 2012. 188(1): p. 29\u201336.","DOI":"10.4049\/jimmunol.1100421"},{"issue":"1","key":"10.1016\/j.intimp.2019.03.055_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.intimp.2019.03.055_bb0030","doi-asserted-by":"crossref","unstructured":"Piao, Y.J., et al., Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro-Oncology, 2012. 14(11): p. 1379\u20131392.","DOI":"10.1093\/neuonc\/nos158"},{"key":"10.1016\/j.intimp.2019.03.055_bb0035","doi-asserted-by":"crossref","unstructured":"Hussain, S.F., et al., The role of human glioma-infiltrating microglia\/macrophages in mediating antitumor immune responses. Neuro-Oncology, 2006. 8(3): p. 261\u2013279.","DOI":"10.1215\/15228517-2006-008"},{"issue":"3","key":"10.1016\/j.intimp.2019.03.055_bb0040","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2019.03.055_bb0045","doi-asserted-by":"crossref","unstructured":"Raychaudhuri, B., et al., Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology, 2011. 13(6): p. 591\u2013599.","DOI":"10.1093\/neuonc\/nor042"},{"key":"10.1016\/j.intimp.2019.03.055_bb0050","doi-asserted-by":"crossref","unstructured":". Dubinski, D., et al., CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro-Oncology, 2016. 18(6): p. 807\u2013818.","DOI":"10.1093\/neuonc\/nov280"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2019.03.055_bb0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jneuroim.2010.03.011","article-title":"Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma plus vaccination model","volume":"223","author":"Jia","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2019.03.055_bb0060","doi-asserted-by":"crossref","unstructured":"Bingisser, R.M., et al., Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3\/STAT5 signaling pathway. J. Immunol., 1998. 160(12): p. 5729\u20135734.","DOI":"10.4049\/jimmunol.160.12.5729"},{"key":"10.1016\/j.intimp.2019.03.055_bb0065","doi-asserted-by":"crossref","unstructured":"Rivoltini, L., et al., Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev., 2002. 188: p. 97\u2013113.","DOI":"10.1034\/j.1600-065X.2002.18809.x"},{"key":"10.1016\/j.intimp.2019.03.055_bb0070","doi-asserted-by":"crossref","unstructured":"Ochoa, A.C., et al., Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res., 2007. 13(2): p. 721S\u2013726S.","DOI":"10.1158\/1078-0432.CCR-06-2197"},{"key":"10.1016\/j.intimp.2019.03.055_bb0075","doi-asserted-by":"crossref","unstructured":"Nakashima, H., et al., Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci. Rep., 2018. 8: p. 10.","DOI":"10.1038\/s41598-017-18540-2"},{"key":"10.1016\/j.intimp.2019.03.055_bb0080","doi-asserted-by":"crossref","unstructured":"Mantovani, A., et al., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol., 2002. 23(11): p. 549\u2013555.","DOI":"10.1016\/S1471-4906(02)02302-5"},{"key":"10.1016\/j.intimp.2019.03.055_bb0085","doi-asserted-by":"crossref","unstructured":"Shinoda, K., et al., CD30 ligand is a new therapeutic target for central nervous system autoimmunity. J. Autoimmun., 2015. 57: p. 14\u201323.","DOI":"10.1016\/j.jaut.2014.11.005"},{"issue":"6","key":"10.1016\/j.intimp.2019.03.055_bb0090","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/mi.2013.18","article-title":"CD30L\/CD30 is critical for maintenance of IL-17A-producing gamma delta T cells bearing V gamma 6 in mucosa-associated tissues in mice","volume":"6","author":"Sun","year":"2013","journal-title":"Mucosal Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2019.03.055_bb0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2567.2006.02354.x","article-title":"Deciphering CD30 ligand biology and its role in humoral immunity","volume":"118","author":"Kennedy","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2019.03.055_bb0100","doi-asserted-by":"crossref","unstructured":"Gruss, H.J., et al., Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood, 1994. 83(8): p. 2045\u201356.","DOI":"10.1182\/blood.V83.8.2045.2045"},{"key":"10.1016\/j.intimp.2019.03.055_bb0105","doi-asserted-by":"crossref","unstructured":"Sun, X., et al., A critical role of CD30 ligand\/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology, 2008. 134(2): p. 447\u2013458.","DOI":"10.1053\/j.gastro.2007.11.004"},{"key":"10.1016\/j.intimp.2019.03.055_bb0110","doi-asserted-by":"crossref","unstructured":"Okonogi, N., et al., Cranial irradiation induces bone marrow-derived microglia in adult mouse brain tissue. J. Radiat. Res., 2014. 55(4): p. 713\u2013719.","DOI":"10.1093\/jrr\/rru015"},{"key":"10.1016\/j.intimp.2019.03.055_bb0115","doi-asserted-by":"crossref","unstructured":"Dejda, A., et al., Neuropilin-1-expressing microglia are associated with nascent retinal vasculature yet dispensable for developmental angiogenesis. Invest. Ophthalmol. Vis. Sci., 2016. 57(4): p. 1530\u20131536.","DOI":"10.1167\/iovs.15-18598"},{"key":"10.1016\/j.intimp.2019.03.055_bb0120","doi-asserted-by":"crossref","unstructured":"Chen, Z.H., et al., Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res., 2017. 77(9): p. 2266\u20132278.","DOI":"10.1158\/0008-5472.CAN-16-2310"},{"key":"10.1016\/j.intimp.2019.03.055_bb0125","doi-asserted-by":"crossref","unstructured":"Bae, E.A., et al., Activation of NKT cells in an anti-PD-1-resistant tumor model enhances antitumor immunity by reinvigorating exhausted CD8 T cells. Cancer Res., 2018. 78(18): p. 5315\u20135326.","DOI":"10.1158\/0008-5472.CAN-18-0734"},{"key":"10.1016\/j.intimp.2019.03.055_bb0130","doi-asserted-by":"crossref","unstructured":"Sun, X., et al., CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. J. Immunol., 2010. 185(12): p. 7671\u20137680.","DOI":"10.4049\/jimmunol.1002229"},{"key":"10.1016\/j.intimp.2019.03.055_bb0135","doi-asserted-by":"crossref","unstructured":"Donson, A.M., et al., Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors. J. Immunol., 2012. 189(4): p. 1920\u20131927.","DOI":"10.4049\/jimmunol.1103373"},{"issue":"4","key":"10.1016\/j.intimp.2019.03.055_bb0140","first-page":"957","article-title":"Flow cytometric characterization of tumor-associated macrophages in experimental gliomas","volume":"46","author":"Badie","year":"2000","journal-title":"Neurosurgery"},{"key":"10.1016\/j.intimp.2019.03.055_bb0145","doi-asserted-by":"crossref","unstructured":"Muller, A., et al., Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells. Int. J. Cancer, 2015. 137(2): p. 278\u2013288.","DOI":"10.1002\/ijc.29379"},{"key":"10.1016\/j.intimp.2019.03.055_bb0150","doi-asserted-by":"crossref","unstructured":"Ostuni, R., et al., Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol., 2015. 36(4): p. 229\u2013239.","DOI":"10.1016\/j.it.2015.02.004"},{"key":"10.1016\/j.intimp.2019.03.055_bb0155","doi-asserted-by":"crossref","unstructured":"Movahedi, K., et al., Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res., 2010. 70(14): p. 5728\u20135739.","DOI":"10.1158\/0008-5472.CAN-09-4672"},{"key":"10.1016\/j.intimp.2019.03.055_bb0160","doi-asserted-by":"crossref","unstructured":"Ugel, S., et al., Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Investig., 2015. 125(9): p. 3365\u20133376.","DOI":"10.1172\/JCI80006"},{"key":"10.1016\/j.intimp.2019.03.055_bb0165","doi-asserted-by":"crossref","unstructured":"Youn, J.I., et al., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol., 2008. 181(8): p. 5791\u20135802.","DOI":"10.4049\/jimmunol.181.8.5791"},{"key":"10.1016\/j.intimp.2019.03.055_bb0170","doi-asserted-by":"crossref","unstructured":"De, I., et al., CSF1 overexpression promotes high-grade glioma formation without impacting the polarization status of glioma-associated microglia and macrophages. Cancer Res., 2016. 76(9): p. 2552\u20132560.","DOI":"10.1158\/0008-5472.CAN-15-2386"},{"key":"10.1016\/j.intimp.2019.03.055_bb0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12974-018-1330-2","article-title":"The IFN-\/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1\/PD-L1 therapy","volume":"15","author":"Qian","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2019.03.055_bb0180","doi-asserted-by":"crossref","unstructured":"Marfia, G., et al., Autocrine\/paracrine sphingosine-1-phosphate fuels proliferative and stemness qualities of glioblastoma stem cells. Glia, 2014. 62(12): p. 1968\u20131981.","DOI":"10.1002\/glia.22718"},{"key":"10.1016\/j.intimp.2019.03.055_bb0185","doi-asserted-by":"crossref","unstructured":"Brandenburg, S., et al., Myeloid cells expressing high level of CD45 are associated with a distinct activated phenotype in glioma. Immunol. Res., 2017. 65(3): p. 757\u2013768.","DOI":"10.1007\/s12026-017-8915-1"},{"key":"10.1016\/j.intimp.2019.03.055_bb0190","doi-asserted-by":"crossref","unstructured":"Horie, R., et al., Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Am. J. Pathol., 2002. 160(5): p. 1647\u20131654.","DOI":"10.1016\/S0002-9440(10)61112-1"},{"key":"10.1016\/j.intimp.2019.03.055_bb0195","doi-asserted-by":"crossref","unstructured":"Pinto, A., et al., The role of eosinophils in the pathobiology of Hodgkin's disease. Ann. Oncol., 1997. 8: p. 89\u201396.","DOI":"10.1093\/annonc\/8.suppl_2.S89"},{"key":"10.1016\/j.intimp.2019.03.055_bb0200","doi-asserted-by":"crossref","unstructured":"Guo, F., et al., TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol. Immunol., 2009. 46(13): p. 2441\u20132448.","DOI":"10.1016\/j.molimm.2009.05.178"},{"issue":"2","key":"10.1016\/j.intimp.2019.03.055_bb0205","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijms19020436","article-title":"When immune cells turn bad-tumor-associated microglia\/macrophages in glioma","volume":"19","author":"Roesch","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2019.03.055_bb0210","doi-asserted-by":"crossref","unstructured":"Umemura, N., et al., Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes\/macrophages that bear M1- and M2-type characteristics. J. Leukoc. Biol., 2008. 83(5): p. 1136\u20131144.","DOI":"10.1189\/jlb.0907611"},{"issue":"4","key":"10.1016\/j.intimp.2019.03.055_bb0215","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2019.03.055_bb0220","doi-asserted-by":"crossref","unstructured":"Lin, E.Y., et al., Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res., 2006. 66(23): p. 11238\u201311246.","DOI":"10.1158\/0008-5472.CAN-06-1278"},{"key":"10.1016\/j.intimp.2019.03.055_bb0225","doi-asserted-by":"crossref","unstructured":"Chae, M., et al., Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Neuro-Oncology, 2015. 17(7): p. 978\u2013991.","DOI":"10.1093\/neuonc\/nou343"},{"key":"10.1016\/j.intimp.2019.03.055_bb0230","doi-asserted-by":"crossref","unstructured":"Rodrigues, J.C., et al., Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-Oncology, 2010. 12(4): p. 351\u2013365.","DOI":"10.1093\/neuonc\/nop023"},{"key":"10.1016\/j.intimp.2019.03.055_bb0235","doi-asserted-by":"crossref","unstructured":"Gustafson, M.P., et al., Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo\/neg monocytes, tumor factors, and dexamethasone. Neuro-Oncology, 2010. 12(7): p. 631\u2013644.","DOI":"10.1093\/neuonc\/noq001"},{"issue":"9","key":"10.1016\/j.intimp.2019.03.055_bb0240","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2019.03.055_bb0245","doi-asserted-by":"crossref","unstructured":"Kumar, V., et al., The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol., 2016. 37(3): p. 208\u2013220.","DOI":"10.1016\/j.it.2016.01.004"},{"key":"10.1016\/j.intimp.2019.03.055_bb0250","doi-asserted-by":"crossref","unstructured":"Nagaraj, S., et al., Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol., 2010. 184(6): p. 3106\u20133116.","DOI":"10.4049\/jimmunol.0902661"},{"key":"10.1016\/j.intimp.2019.03.055_bb0255","doi-asserted-by":"crossref","unstructured":"Nagaraj, S., et al., Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med., 2007. 13(7): p. 828\u2013835.","DOI":"10.1038\/nm1609"},{"key":"10.1016\/j.intimp.2019.03.055_bb0260","doi-asserted-by":"crossref","unstructured":"Kusmartsev, S., et al., Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol., 2004. 172(2): p. 989\u2013999.","DOI":"10.4049\/jimmunol.172.2.989"},{"issue":"2","key":"10.1016\/j.intimp.2019.03.055_bb0265","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.it.2016.11.005","article-title":"T cell exhaustion in glioblastoma: intricacies of immune checkpoints","volume":"38","author":"Mirzaei","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2019.03.055_bb0270","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2019.03.055_bb0275","doi-asserted-by":"crossref","unstructured":"Barber, D.L., et al., Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 2006. 439(7077): p. 682\u2013687.","DOI":"10.1038\/nature04444"},{"key":"10.1016\/j.intimp.2019.03.055_bb0280","doi-asserted-by":"crossref","unstructured":"Topalian, S.L., et al., Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer, 2016. 16(5): p. 275\u2013287.","DOI":"10.1038\/nrc.2016.36"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918308427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918308427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:11:39Z","timestamp":1761585099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576918308427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":56,"alternative-id":["S1567576918308427"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.03.055","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD30 ligand deficiency accelerates glioma progression by promoting the formation of tumor immune microenvironment","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.03.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}